about
Step-down of enalapril treatment for arterial hypertensionIs 6-month GRACE risk score a useful tool to predict stroke after an acute coronary syndrome?Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome.Anaemia is associated with higher mortality among patients with heart failure with preserved systolic functionPredictive value of advanced glycation end products for the development of post-infarction heart failure: a preliminary report.Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome.Alteration of platelet GPVI signaling in ST-elevation myocardial infarction patients demonstrated by a combination of proteomic, biochemical, and functional approaches.Optimal Medical Therapy in Patients with Malignancy Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome: a BleeMACS Sub-Study.Clinical profile and outcomes in octogenarians with atrial fibrillation: A community-based study in a specific European health care area.Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction.Impact of blood transfusion on in-hospital myocardial infarctions according to patterns of acute coronary syndrome: Insights from the BleeMACS registry.Safety and effectiveness of the new P2Y12r inhibitor agents vs clopidogrel in ACS patients according to the geographic area: East Asia vs Europe.Mehran contrast nephropathy risk score: Is it still useful 10 years later?Mortality and cardiovascular morbidity within 30 days of discharge following acute coronary syndrome in a contemporary European cohort of patients: How can early risk prediction be improved? The six-month GRACE risk score.BleeMACS: rationale and design of the study.Prognostic Benefit of Beta-blockers After Acute Coronary Syndrome With Preserved Systolic Function. Still Relevant Today?Admission and fasting plasma glucose for estimating risk of death of diabetic and nondiabetic patients with acute coronary syndrome: nonlinearity of hazard ratios and time-dependent comparison.Letter by Raposeiras-Roubin et al regarding article, "mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis".Results of intra-aortic balloon counterpulsation in patients with st-elevation myocardial infarction with cardiogenic shock undergoing percutaneous coronary intervention: is there a benefit?GRACE risk score predicts contrast-induced nephropathy in patients with acute coronary syndrome and normal renal function.Incidence and prognostic value of infections during an acute coronary syndrome: a single center experience.Creatinine-or cystatin C-based equations to estimate glomerular filtration rate in acute myocardial infarction: a disparity in estimating renal function and in mortality risk prediction.Prognostic influence of prior ischemic heart disease in in-hospital mortality of acute coronary syndromes.Risk stratification for the development of heart failure after acute coronary syndrome at the time of hospital discharge: Predictive ability of GRACE risk score.Relative performance of three formulas to assess renal function at predicting in-hospital hemorrhagic complications in an acute coronary syndrome population. What does the new CKD-EPI formula provide?[Long-term trends in drug prescription for hospitalized patients with congestive heart failure. Influence of type of dysfunction].Omentin treatment of epicardial fat improves its anti-inflammatory activity and paracrine benefit on smooth muscle cells.Proposal of a novel clinical score to predict heart failure incidence in long-term survivors of acute coronary syndromes.Additive value of the CRUSADE score to the GRACE score for mortality risk prediction in patients with acute coronary syndromes.Statins modulate feedback regulation mechanisms between advanced glycation end-products and C-reactive protein: evidence in patients with acute myocardial infarction.Therapeutic strategy in patients with severe anemia admitted for non-ST-segment elevation acute coronary syndrome and prognostic impact.A comparison of the CKD-EPI, MDRD-4, and Cockcroft-Gault equations to assess renal function in predicting all-cause mortality in acute coronary syndrome patients.Glucose and Inflammatory Cells Decrease Adiponectin in Epicardial Adipose Tissue Cells: Paracrine Consequences on Vascular Endothelium.Association of Beta-Blockers with Survival on Patients Presenting with ACS Treated with PCI: A Propensity Score Analysis from the BleeMACS Registry.Prevalence, long-term prognosis and medical alternatives for patients admitted for acute coronary syndromes and prasugrel contraindicationA multicentre randomized pilot trial on the effectiveness of different levels of cooling in comatose survivors of out-of-hospital cardiac arrest: the FROST-I trialIncidence and predictors of stroke in patients discharged with the diagnosis of acute coronary syndromeA prospective study of the clinical outcomes and prognosis associated with comorbid COPD in the atrial fibrillation populationPlasma leukocyte elastase concentration in angiographically diagnosed coronary artery diseaseDoppler echocardiographic comparison of small (19 mm) bileaflet and pericardial heart valve prostheses in aortic position
P50
Q28377696-6616220C-075E-4EF6-A666-7A9132578916Q34768331-939A4E31-EF0F-48C2-AB4A-C0BE6C6FCA65Q34994616-8164F040-8654-4F6C-A780-AE35534F7B6AQ35770879-77B6E009-0662-4C3B-9660-F0689A7CCC01Q36373255-1BE076CA-24F4-433F-A1A7-0765B455D185Q37140945-01679452-431F-46EB-B37C-01DF9D9EA9DEQ37526189-86C18197-E7BD-4088-9EA1-0CD44E18E47BQ38386616-88B295D3-432C-4C00-B596-C51CE9D951E7Q38659812-7B17B6AB-E410-427A-B900-EEFE8B00CBBAQ39171906-BDBF63E2-A476-4290-B5CC-CB90E5EE34BFQ39610008-4898EF03-907C-4A78-A097-601A79BD167BQ40661859-118BEDA2-D63E-4788-8443-BD434B00B344Q40743429-6C911F21-C765-4C2B-8C2A-73560EAB80D4Q40861082-518A0579-643A-4CB2-BA7C-E5F05DC512D7Q40941750-A8488F32-21C5-4BDE-900C-54B2142D27AFQ41685750-0BAEFB24-2D0E-4664-8BB9-25EE6B39365DQ43230593-253C5E90-97A3-4EEE-8C74-8575B00C978CQ43533869-036E281D-A4D5-4109-99FD-E733C126358CQ43771892-D059BBB8-50AE-4ACB-BA46-BFC12EFB24FFQ44314100-0E7E8B6B-B785-4871-B072-66EF97214AD8Q44361732-4DEDE16E-524D-4B23-B225-A924D0F9A775Q44616276-25450486-803C-4C73-B559-208B01982428Q44633899-F44EEC19-B1E4-4636-A9C3-16352F970716Q44703346-0B09F0AA-9E72-4883-8D1F-29750C01D787Q44878583-2CA950FF-71D4-4706-BC2C-49A91A98A509Q46451635-1CE53EAB-91F8-466D-8856-61C32AF30BB6Q48248803-ACEC91F2-175B-47BB-AE73-FDB6F7ABED68Q50197812-0A2A219F-81DB-4CF9-BFCB-63B2AD447109Q50200804-9DDDE0B0-0959-4781-9591-0B5316D413ADQ51001320-5891CF4D-0767-4EB0-9FD1-71EFDF523EA4Q51030957-6D2FD12A-A05C-4EA3-A944-0A527A6C2C37Q51291119-4C1B78E5-66D0-42F4-BDF4-CF16803F4D3EQ51707502-5BB90BEF-6CDA-4AE9-ABA6-1647DED6BBADQ54650216-B5282A3D-A0D5-49BD-B76B-DCD75991D2DCQ56761534-9070C25E-BED5-4D40-89B0-1634D675AE2CQ57806607-6C531232-F197-4A88-A780-0A7173457003Q58554910-51A2E399-F617-4074-868E-4F6158F4EAF4Q64227971-7EF1EF11-5B03-4AB1-9FCE-A7B8E7D5F9E3Q71814642-66D78CB1-ABA8-438F-98A4-138F980534CAQ71983138-8772E380-B106-4C33-BAC2-4184E000F5D3
P50
description
Forscher
@de
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究員
@ja
研究者
@zh
name
J García-Acuña
@en
J García-Acuña
@nl
type
label
J García-Acuña
@en
J García-Acuña
@nl
prefLabel
J García-Acuña
@en
J García-Acuña
@nl
P106
P31
P496
0000-0003-0119-1710